Celgene
| Company type | Defunct |
|---|---|
| Nasdaq: CELG | |
| Industry | Biotechnology |
| Founded | 1986 |
| Founder | Sol J. Barer |
| Defunct | November 21, 2019 |
| Fate | Acquired by Bristol Myers Squibb |
| Headquarters | Summit, New Jersey, U.S. |
Key people | Robert J. Hugin (executive chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue | $15.281 billion (2018) |
| $4.046 billion (2018) | |
| Total assets | $35.480 billion (2018) |
| Total equity | $6.161 billion (2018) |
Number of employees | 8,852 (2018) |
| Footnotes / references | |
Celgene Corporation, headquartered in Summit, New Jersey, was a pharmaceutical company that produced cancer and immunology drugs. Its primary products were Revlimid (lenalidomide), which is used in the treatment of multiple myeloma (63% of 2018 revenues); Pomalyst and Imnovid (Pomalidomide), also used in the treatment of multiple myeloma (13% of 2018 revenues); and Otezla (Apremilast), used in the treatment of psoriasis (11% of 2018 revenues). In 2018, 66% of the company's revenues came from the United States. In 2019, the company was acquired by Bristol Myers Squibb (BMS); as part of the acquisition, Otezla was sold to Amgen.